• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results

    10/25/23 4:06:00 PM ET
    $SLP
    EDP Services
    Technology
    Get the next $SLP alert in real time by email

    Fiscal 2023 revenue increased 11% year-over-year to $59.6 million

    Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68

    Simulations Plus to host its Investor Day on November 14, 2023

    Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023.

    Fourth Quarter Financial Highlights

    • Total revenue increased 33% to $15.6 million
    • Software revenue increased 59% to $9.3 million, representing 60% of total revenue
    • Services revenue increased 8% to $6.3 million, representing 40% of total revenue
    • Gross profit increased 35% to $12.3 million; gross margin was 78%
    • Adjusted EBITDA of $4.9 million, representing 31% of total revenue
    • Adjusted EPS of $0.18
    • Net income of $0.5 million and diluted earnings per share (EPS) of $0.03, compared to net income of $1.0 million and diluted EPS of $0.05 in the fourth quarter of 2022

    Full Year Financial Highlights

    • Total revenue increased 11% to $59.6 million
    • Software revenue increased 12% to $36.5 million, representing 61% of total revenue
    • Services revenue increased 8% to $23.1 million, representing 39% of total revenue
    • Gross profit increased 11% to $47.9 million; gross margin was 80%
    • Adjusted EBITDA of $20.6 million, representing 35% of total revenue
    • Adjusted EPS of $0.67
    • Net income of $10.0 million and diluted EPS of $0.49, compared to net income of $12.5 million and diluted EPS of $0.60 in fiscal 2022

    Management Commentary

    "We delivered strong revenue and earnings results for fiscal 2023, marked by our team's impressive execution on building strong customer relationships," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Our ability to drive growth while navigating a challenging environment demonstrates the strength of our customer-centric business model and the effort and dedication of our colleagues throughout the year."

    "Fourth quarter revenue increased 33% year-over-year, driven by strong contribution across our software segment offerings, with notable performance by GastroPlus, and solid performance in our services offering, especially in our quantitative systems pharmacology (QSP) business unit, which benefitted from our Immunetrics acquisition in the quarter. Gross margins for the fourth quarter remained strong at 78%, reflecting a favorable mix of higher margin software sales and our ability to pass along price increases. We achieved our fiscal 2023 guidance for both revenue and adjusted diluted EPS."

    "Our renewal harmonization initiative to simplify and align contract renewals played out as expected and is essentially complete. We achieved our goal of gaining greater visibility into our revenues, and with contract harmonization now embedded in the normal course of our business processes, we expect that both Simulations Plus and our customers will see the benefits going forward."

    "The integration of Immunetrics is going well. Immunetrics brings its strong reputation in the immunology and oncology markets and has a healthy pipeline, including new accounts sourced from our Simulations Plus customer base."

    "We believe that we enter fiscal 2024 well-positioned for continued growth. The underlying fundamentals of our market are resilient, our pipeline is healthy, our profitability is strong, and our balance sheet is sound. Our team remains committed to innovative and disciplined growth that delivers long-term returns for our shareholders."

    Fiscal 2024 Guidance

     

     

    Fiscal 2024 Guidance

     

    Annual Increase

    Revenue

     

    $66M - $69M

     

    10 - 15%

    Software mix

     

    55 - 60%

     

    —

    Services mix

     

    40 - 45%

     

    —

    Diluted earnings per share

     

    $0.66 - $0.68

     

    35 - 39%

    Quarterly Dividend

    The Company's Board of Directors declared a cash dividend of $0.06 per share of the Company's common stock, payable on November 6, 2023, to shareholders of record as of October 30, 2023. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.

    Environmental, Social, and Governance

    We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our ESG website.

    Webcast and Conference Call Details

    Shawn O'Connor, chief executive officer, and Will Frederick, chief financial officer, will host a conference call and webcast today at 5 p.m. Eastern Time to discuss the details of the Company's performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 or 1-201-389-0879. The webcast will be available on our website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

    Investor Day

    Simulations Plus will host a virtual Investor Day on Tuesday, November 14, 2023. Presentations will be made by CEO Shawn O'Connor, CFO Will Frederick and business unit leaders. The presentations will provide an in-depth overview of Simulations Plus' paths to win through stronger customer alignment, its growth strategy, and financial outlook. Attendance is by invitation only to institutional investors and analysts. Presentations are expected to begin at 1:00 p.m. ET, and the event is expected to conclude at 3:00 p.m. ET. Dial-in information will be available at a later date, and a more detailed agenda, presentations and a live webcast will be available on the day of the event on the Simulations Plus website at https://www.simulations-plus.com/investorscorporate-profile/conference-calls/. A replay and transcript of the webcast will be available shortly after the event.

    Non-GAAP Definitions

    Adjusted EBITDA

    Adjusted EBITDA is defined as earnings (loss) before interest, taxes, depreciation and amortization, stock-based compensation, (gain) loss on currency exchange, any acquisition- or financial-transaction-related expenses, and any asset impairment charges. Currency exchange excluded represents the exchange rate fluctuations on the foreign currency denominated transactions. The impact of transactions in foreign currency represents the effect of converting revenue and expenses occurring in a currency other than the functional currency. The Company believes that the non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company's management uses non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results, for internal planning and forecasting purposes and in the calculation of performance-based compensation. Adjusted EBITDA represents a measure that we believe is customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that Adjusted EBITDA is useful in evaluating our core operating results. However, Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income or operating income as an indicator of our operating performance or to net cash provided by operating activities as a measure of our liquidity. The Company's Adjusted EBITDA measure may not provide information that is directly comparable to that provided by other companies in its industry, as other companies in its industry may calculate non-GAAP financial results differently, particularly related to nonrecurring, unusual items.

    Adjusted Diluted EPS

    Adjusted diluted EPS is calculated based on net income excluding the impact of any acquisition- or financial-transaction-related expenses, any asset impairment charges, and tax provisions / benefits related to the previous items. The Company excludes the above items because they are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

    The Company believes that the use of non-GAAP measures helps investors to gain a better understanding of the Company's core operating results and future prospects, consistent with how management measures and forecasts the Company's performance, especially when comparing such results to previous periods or forecasts.

    About Simulations Plus

    Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at https://www.simulations-plus.com/. Follow us on LinkedIn | Twitter | YouTube.

    Forward-Looking Statements

    Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "expect," and "anticipate" mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Immunetrics business with our own, as well as expenses we may incur in connection therewith, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

    SIMULATIONS PLUS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

     

     

     

    Years ended August 31,

    (in thousands, except per common share amounts)

     

     

    2023

     

     

     

    2022

     

     

     

    2021

     

    Revenues

     

     

     

     

     

     

    Software

     

    $

    36,517

     

     

    $

    32,642

     

     

    $

    27,670

     

    Services

     

     

    23,060

     

     

     

    21,264

     

     

     

    18,796

     

    Total revenues

     

     

    59,577

     

     

     

    53,906

     

     

     

    46,466

     

    Cost of revenues

     

     

     

     

     

     

    Software

     

     

    3,627

     

     

     

    3,060

     

     

     

    3,235

     

    Services

     

     

    8,003

     

     

     

    7,762

     

     

     

    7,365

     

    Total cost of revenues

     

     

    11,630

     

     

     

    10,822

     

     

     

    10,600

     

    Gross profit

     

     

    47,947

     

     

     

    43,084

     

     

     

    35,866

     

    Operating expenses

     

     

     

     

     

     

    Research and development

     

     

    4,504

     

     

     

    3,208

     

     

     

    4,047

     

    Selling, general, and administrative

     

     

    34,718

     

     

     

    24,965

     

     

     

    20,566

     

    Total operating expenses

     

     

    39,222

     

     

     

    28,173

     

     

     

    24,613

     

     

     

     

     

     

     

     

    Income from operations

     

     

    8,725

     

     

     

    14,911

     

     

     

    11,253

     

     

     

     

     

     

     

     

    Other income (expense), net

     

     

    2,970

     

     

     

    204

     

     

     

    (168

    )

     

     

     

     

     

     

     

    Income before income taxes

     

     

    11,695

     

     

     

    15,115

     

     

     

    11,085

     

    Provision for income taxes

     

     

    (1,734

    )

     

     

    (2,632

    )

     

     

    (1,303

    )

    Net income

     

    $

    9,961

     

     

    $

    12,483

     

     

    $

    9,782

     

     

     

     

     

     

     

     

    Earnings per share

     

     

     

     

     

     

    Basic

     

    $

    0.50

     

     

    $

    0.62

     

     

    $

    0.49

     

    Diluted

     

    $

    0.49

     

     

    $

    0.60

     

     

    $

    0.47

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding

     

     

     

     

     

     

    Basic

     

     

    20,075

     

     

     

    20,196

     

     

     

    20,045

     

    Diluted

     

     

    20,465

     

     

     

    20,749

     

     

     

    20,743

     

     

     

     

     

     

     

     

    Other comprehensive income (loss), net of tax

     

     

     

     

     

     

    Foreign currency translation adjustments

     

     

    167

     

     

     

    (265

    )

     

     

    (101

    )

    Comprehensive income

     

    $

    10,128

     

     

    $

    12,218

     

     

    $

    9,681

     

     

    SIMULATIONS PLUS, INC.

    CONSOLIDATED BALANCE SHEETS

     

    (in thousands, except share and per share amounts)

     

    August 31, 2023

     

    August 31, 2022

    ASSETS

     

     

     

     

    Current assets

     

     

     

     

    Cash and cash equivalents

     

    $

    57,523

     

     

    $

    51,567

     

    Accounts receivable, net of allowance for doubtful accounts of $46 and $12

     

     

    10,201

     

     

     

    13,787

     

    Prepaid income taxes

     

     

    804

     

     

     

    1,391

     

    Prepaid expenses and other current assets

     

     

    3,904

     

     

     

    3,377

     

    Short-term investments

     

     

    57,940

     

     

     

    76,668

     

    Total current assets

     

     

    130,372

     

     

     

    146,790

     

    Long-term assets

     

     

     

     

    Capitalized computer software development costs, net of accumulated amortization of $17,199 and $15,672

     

     

    11,335

     

     

     

    9,563

     

    Property and equipment, net

     

     

    671

     

     

     

    632

     

    Operating lease right-of-use assets

     

     

    1,247

     

     

     

    1,420

     

    Intellectual property, net of accumulated amortization of $9,301 and $7,928

     

     

    8,689

     

     

     

    9,057

     

    Other intangible assets, net of accumulated amortization of $2,107 and $2,662

     

     

    12,825

     

     

     

    7,560

     

    Goodwill

     

     

    19,099

     

     

     

    12,921

     

    Deferred tax assets

     

     

    1,438

     

     

     

    —

     

    Other assets

     

     

    425

     

     

     

    439

     

    Total assets

     

    $

    186,101

     

     

    $

    188,382

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

     

    Current liabilities

     

     

     

     

    Accounts payable

     

    $

    144

     

     

    $

    225

     

    Accrued compensation

     

     

    4,392

     

     

     

    3,254

     

    Accrued expenses

     

     

    659

     

     

     

    931

     

    Contracts payable

     

     

    3,250

     

     

     

    —

     

    Operating lease liability - current portion

     

     

    442

     

     

     

    461

     

    Deferred revenue

     

     

    3,100

     

     

     

    2,864

     

    Total current liabilities

     

     

    11,987

     

     

     

    7,735

     

    Long-term liabilities

     

     

     

     

    Deferred income taxes, net

     

     

    —

     

     

     

    1,456

     

    Operating lease liability

     

     

    755

     

     

     

    943

     

    Contracts payable – net of current portion

     

     

    3,330

     

     

     

    —

     

    Total liabilities

     

     

    16,072

     

     

     

    10,134

     

    Commitments and contingencies

     

     

    —

     

     

     

    —

     

    Shareholders' equity

     

     

     

     

    Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued and outstanding

     

    $

    —

     

     

    $

    —

     

    Common stock, $0.001 par value and additional paid-in capital —50,000,000 shares authorized; 19,937,961 and 20,260,070 shares issued and outstanding

     

     

    144,974

     

     

     

    138,512

     

    Retained earnings

     

     

    25,196

     

     

     

    40,044

     

    Accumulated other comprehensive loss

     

     

    (141

    )

     

     

    (308

    )

    Total shareholders' equity

     

     

    170,029

     

     

     

    178,248

     

    Total liabilities and shareholders' equity

     

    $

    186,101

     

     

    $

    188,382

     

     

    SIMULATIONS PLUS, INC.

    Trended Financial Information*

    (Unaudited)

     

    (in millions except earnings per share amounts)

     

     

     

    FY 2022

     

    FY 2023

     

     

    2022

     

     

     

    2023

     

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    FY

     

    FY

    Revenue

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Software

     

    $

    7.4

     

     

    $

    9.8

     

     

    $

    9.6

     

     

    $

    5.9

     

     

    $

    6.1

     

     

    $

    10.5

     

     

    $

    10.6

     

     

    $

    9.3

     

     

    $

    32.7

     

     

    $

    36.5

     

    Services

     

     

    5.0

     

     

     

    5.0

     

     

     

    5.3

     

     

     

    5.8

     

     

     

    5.9

     

     

     

    5.3

     

     

     

    5.6

     

     

     

    6.3

     

     

     

    21.2

     

     

     

    23.1

     

    Total

     

    $

    12.4

     

     

    $

    14.8

     

     

    $

    15.0

     

     

    $

    11.7

     

     

    $

    12.0

     

     

    $

    15.8

     

     

    $

    16.2

     

     

    $

    15.6

     

     

    $

    53.9

     

     

    $

    59.6

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross Margin

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Software

     

     

    90.0

    %

     

     

    92.0

    %

     

     

    92.4

    %

     

     

    86.1

    %

     

     

    85.4

    %

     

     

    92.0

    %

     

     

    91.5

    %

     

     

    89.4

    %

     

     

    90.6

    %

     

     

    90.1

    %

    Services

     

     

    60.0

    %

     

     

    59.3

    %

     

     

    65.6

    %

     

     

    68.2

    %

     

     

    69.7

    %

     

     

    66.2

    %

     

     

    63.4

    %

     

     

    62.1

    %

     

     

    63.5

    %

     

     

    65.3

    %

    Total

     

     

    77.8

    %

     

     

    80.9

    %

     

     

    82.9

    %

     

     

    77.2

    %

     

     

    77.7

    %

     

     

    83.4

    %

     

     

    81.8

    %

     

     

    78.4

    %

     

     

    79.9

    %

     

     

    80.5

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Income from operations

     

    $

    3.8

     

     

    $

    5.5

     

     

    $

    4.9

     

     

    $

    0.7

     

     

    $

    0.9

     

     

    $

    4.0

     

     

    $

    4.1

     

     

    $

    (0.3

    )

     

    $

    14.9

     

     

    $

    8.7

     

    Operating Margin

     

     

    30.6

    %

     

     

    37.0

    %

     

     

    33.1

    %

     

     

    5.9

    %

     

     

    7.3

    %

     

     

    25.6

    %

     

     

    25.2

    %

     

     

    -1.8

    %

     

     

    27.7

    %

     

     

    14.6

    %

    Net Income

     

    $

    3.0

     

     

    $

    4.4

     

     

    $

    4.1

     

     

    $

    1.0

     

     

    $

    1.2

     

     

    $

    4.2

     

     

    $

    4.0

     

     

    $

    0.5

     

     

    $

    12.5

     

     

    $

    10.0

     

    Diluted Earnings Per Share

     

    $

    0.15

     

     

    $

    0.21

     

     

    $

    0.20

     

     

    $

    0.05

     

     

    $

    0.06

     

     

    $

    0.20

     

     

    $

    0.20

     

     

    $

    0.03

     

     

    $

    0.60

     

     

    $

    0.49

     

    Adjusted EBITDA

     

    $

    5.3

     

     

    $

    7.2

     

     

    $

    6.5

     

     

    $

    2.5

     

     

    $

    3.0

     

     

    $

    6.2

     

     

    $

    6.5

     

     

    $

    4.9

     

     

    $

    21.5

     

     

    $

    20.6

     

    Adjusted Diluted EPS

     

    $

    0.15

     

     

    $

    0.21

     

     

    $

    0.20

     

     

    $

    0.06

     

     

    $

    0.07

     

     

    $

    0.21

     

     

    $

    0.21

     

     

    $

    0.18

     

     

    $

    0.61

     

     

    $

    0.67

     

    Cash Flow from Operations

     

    $

    3.6

     

     

    $

    2.6

     

     

    $

    3.8

     

     

    $

    7.9

     

     

    $

    4.7

     

     

    $

    5.5

     

     

    $

    8.5

     

     

    $

    3.1

     

     

    $

    17.9

     

     

    $

    21.9

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue Breakdown by Region

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Americas

     

    $

    8.5

     

     

    $

    9.7

     

     

    $

    11.2

     

     

    $

    8.4

     

     

    $

    8.5

     

     

    $

    10.6

     

     

    $

    10.8

     

     

    $

    11.0

     

     

    $

    37.7

     

     

    $

    40.8

     

    EMEA

     

     

    3.0

     

     

     

    3.7

     

     

     

    1.9

     

     

     

    1.7

     

     

     

    2.1

     

     

     

    3.6

     

     

     

    3.4

     

     

     

    2.6

     

     

     

    10.4

     

     

     

    11.7

     

    Asia Pacific

     

     

    0.9

     

     

     

    1.4

     

     

     

    1.9

     

     

     

    1.6

     

     

     

    1.3

     

     

     

    1.5

     

     

     

    2.1

     

     

     

    2.1

     

     

     

    5.8

     

     

     

    7.0

     

    Total

     

    $

    12.4

     

     

    $

    14.8

     

     

    $

    15.0

     

     

    $

    11.7

     

     

    $

    12.0

     

     

    $

    15.8

     

     

    $

    16.2

     

     

    $

    15.6

     

     

    $

    53.9

     

     

    $

    59.6

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Software Performance Metrics

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Average Revenue per Customer (in 000s)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Commercial

     

    $

    71.0

     

     

    $

    101.0

     

     

    $

    95.0

     

     

    $

    65.0

     

     

    $

    68.0

     

     

    $

    110.0

     

     

    $

    97.0

     

     

    $

    88.0

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Services Performance Metrics

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Backlog

     

    $

    15.4

     

     

    $

    17.0

     

     

    $

    16.7

     

     

    $

    15.9

     

     

    $

    15.8

     

     

    $

    15.4

     

     

    $

    15.7

     

     

    $

    19.5

     

     

     

     

     

    *Numbers may not add due to rounding

     

    SIMULATIONS PLUS, INC.

    Reconciliation of Adjusted EBITDA to Net Income*

    (Unaudited)

     

    (in millions)

     

     

     

    FY 2022

     

    FY 2023

     

     

    2022

     

     

     

    2023

     

     

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    FY

     

    FY

    Net Income

     

    $

    3.0

     

     

    $

    4.4

     

     

    $

    4.1

     

     

    $

    1.0

     

     

    $

    1.2

     

     

    $

    4.2

     

     

    $

    4.0

     

     

    $

    0.5

     

     

    $

    12.5

     

     

    $

    10.0

     

    Excluding:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Interest income and expense, net

     

     

    (0.1

    )

     

     

    (0.1

    )

     

     

    (0.1

    )

     

     

    (0.4

    )

     

     

    (0.8

    )

     

     

    (1.0

    )

     

     

    (1.1

    )

     

     

    (1.3

    )

     

     

    (0.7

    )

     

     

    (4.1

    )

    Provision for income taxes

     

     

    0.8

     

     

     

    1.1

     

     

     

    0.7

     

     

     

    (0.1

    )

     

     

    0.4

     

     

     

    0.9

     

     

     

    0.9

     

     

     

    (0.5

    )

     

     

    2.6

     

     

     

    1.7

     

    Depreciation and amortization

     

     

    0.8

     

     

     

    1.0

     

     

     

    0.9

     

     

     

    0.9

     

     

     

    0.9

     

     

     

    0.9

     

     

     

    0.9

     

     

     

    1.1

     

     

     

    3.6

     

     

     

    3.9

     

    Stock-based compensation

     

     

    0.6

     

     

     

    0.7

     

     

     

    0.7

     

     

     

    0.7

     

     

     

    0.9

     

     

     

    1.2

     

     

     

    1.1

     

     

     

    1.1

     

     

     

    2.7

     

     

     

    4.2

     

    (Gain) loss on currency exchange

     

     

    (0.1

    )

     

     

    (0.1

    )

     

     

    0.2

     

     

     

    0.2

     

     

     

    —

     

     

     

    —

     

     

     

    0.3

     

     

     

    0.2

     

     

     

    0.2

     

     

     

    0.5

     

    Impairment of other intangibles

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.5

     

     

     

    —

     

     

     

    0.5

     

    Change in value of contingent consideration

     

     

    0.1

     

     

     

    0.1

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.7

     

     

     

    0.3

     

     

     

    0.7

     

    Mergers & Acquisitions expense

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.3

     

     

     

    0.3

     

     

     

    0.1

     

     

     

    0.4

     

     

     

    2.5

     

     

     

    0.3

     

     

     

    3.3

     

    Adjusted EBITDA

     

    $

    5.3

     

     

    $

    7.2

     

     

    $

    6.5

     

     

    $

    2.5

     

     

    $

    3.0

     

     

    $

    6.2

     

     

    $

    6.5

     

     

    $

    4.9

     

     

    $

    21.5

     

     

    $

    20.6

     

    *Numbers may not add due to rounding

     

    SIMULATIONS PLUS, INC.

    Reconciliation of Adjusted Diluted EPS to Diluted EPS*

    (Unaudited)

     

    (in millions, except Diluted EPS and Adjusted Diluted EPS)

     

     

     

    FY 2022

     

    FY 2023

     

     

    2022

     

     

     

    2023

     

     

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    FY

     

    FY

    Net Income (GAAP)

     

    $

    3.0

     

    $

    4.4

     

    $

    4.1

     

    $

    1.0

     

     

    $

    1.2

     

     

    $

    4.2

     

    $

    4.0

     

     

    $

    0.5

     

     

    $

    12.5

     

     

    $

    10.0

     

    Excluding:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Mergers & Acquisitions expense

     

     

    —

     

     

    —

     

     

    —

     

     

    0.3

     

     

     

    0.3

     

     

     

    0.1

     

     

    0.4

     

     

     

    0.9

     

     

     

    0.3

     

     

     

    1.7

     

    Immunetrics transaction costs

     

     

    —

     

     

    —

     

     

    —

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

    —

     

     

     

    2.3

     

     

     

    —

     

     

     

    2.3

     

    Cognigen trade name write-off

     

     

    —

     

     

    —

     

     

    —

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

    —

     

     

     

    0.5

     

     

     

    —

     

     

     

    0.5

     

    Tax effect on above adjustments

     

     

    —

     

     

    —

     

     

    —

     

     

    (0.1

    )

     

     

    (0.1

    )

     

     

    —

     

     

    (0.1

    )

     

     

    (0.5

    )

     

     

    (0.1

    )

     

     

    (0.7

    )

    Adjusted Net income (Non-GAAP)

     

    $

    3.0

     

    $

    4.4

     

    $

    4.1

     

    $

    1.2

     

     

    $

    1.5

     

     

    $

    4.2

     

    $

    4.3

     

     

    $

    3.7

     

     

    $

    12.8

     

     

    $

    13.8

     

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted

     

     

    20.7

     

     

    20.7

     

     

    20.8

     

     

    20.9

     

     

     

    20.8

     

     

     

    20.5

     

     

    20.4

     

     

     

    20.4

     

     

     

    20.7

     

     

     

    20.5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted EPS (GAAP)

     

    $

    0.15

     

    $

    0.21

     

    $

    0.20

     

    $

    0.05

     

     

    $

    0.06

     

     

    $

    0.20

     

    $

    0.20

     

     

    $

    0.03

     

     

    $

    0.60

     

     

    $

    0.49

     

    Adjusted Diluted EPS (Non-GAAP)

     

    $

    0.15

     

    $

    0.21

     

    $

    0.20

     

    $

    0.06

     

     

    $

    0.07

     

     

    $

    0.21

     

    $

    0.21

     

     

    $

    0.18

     

     

    $

    0.61

     

     

    $

    0.67

     

    *Numbers may not add due to rounding

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231025046790/en/

    Get the next $SLP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLP

    DatePrice TargetRatingAnalyst
    12/18/2025Buy → Neutral
    BTIG Research
    9/30/2025$16.00Hold
    TD Cowen
    7/15/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    11/15/2024$39.00Overweight
    Stephens
    7/29/2024$47.00Overweight
    KeyBanc Capital Markets
    7/16/2024Mkt Perform
    JMP Securities
    6/28/2024Outperform
    William Blair
    5/9/2023$55.00Buy
    BTIG Research
    More analyst ratings

    $SLP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Simulations Plus downgraded by BTIG Research

    BTIG Research downgraded Simulations Plus from Buy to Neutral

    12/18/25 9:02:23 AM ET
    $SLP
    EDP Services
    Technology

    TD Cowen initiated coverage on Simulations Plus with a new price target

    TD Cowen initiated coverage of Simulations Plus with a rating of Hold and set a new price target of $16.00

    9/30/25 8:58:03 AM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Simulations Plus from Overweight to Sector Weight

    7/15/25 8:39:07 AM ET
    $SLP
    EDP Services
    Technology

    $SLP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Revenue Officer Dibella John Anthony Ii exercised 10,300 shares at a strike of $9.71, increasing direct ownership by 13% to 90,140 units (SEC Form 4)

    4 - Simulations Plus, Inc. (0001023459) (Issuer)

    2/9/26 4:08:21 PM ET
    $SLP
    EDP Services
    Technology

    Director Woltosz Walter S was granted 1,776 shares, increasing direct ownership by 0.05% to 3,280,683 units (SEC Form 4)

    4 - Simulations Plus, Inc. (0001023459) (Issuer)

    2/2/26 4:18:28 PM ET
    $SLP
    EDP Services
    Technology

    Director Evans Sharlene was granted 1,776 shares, increasing direct ownership by 13% to 15,056 units (SEC Form 4)

    4 - Simulations Plus, Inc. (0001023459) (Issuer)

    2/2/26 4:12:12 PM ET
    $SLP
    EDP Services
    Technology

    $SLP
    SEC Filings

    View All

    Simulations Plus Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Simulations Plus, Inc. (0001023459) (Filer)

    2/18/26 4:07:44 PM ET
    $SLP
    EDP Services
    Technology

    SEC Form DEFA14A filed by Simulations Plus Inc.

    DEFA14A - Simulations Plus, Inc. (0001023459) (Filer)

    2/4/26 4:10:05 PM ET
    $SLP
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Simulations Plus Inc.

    SCHEDULE 13G - Simulations Plus, Inc. (0001023459) (Subject)

    1/30/26 2:45:59 PM ET
    $SLP
    EDP Services
    Technology

    $SLP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations

    Extended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). The extended projects support ongoing federal research efforts focused on the development of new approach methodologies (NAMs) and advancing computational approaches for food and chemi

    2/9/26 6:45:00 PM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus to Participate in Upcoming Investor Conferences

    Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the upcoming investor conferences: BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Format: One-on-one meetings When: Tuesday, February 10, 2026 Location: Snowbird, Utah TD Cowen 46th Annual Health Care Conference Format: Fireside chat and one-on-one meetings When: Tuesday, March 3, 2026 Location: Boston, Massachusetts KeyBanc Healthcare Forum Format: Fireside chat and one-on-one meetings When: W

    2/3/26 4:05:00 PM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day

    Showcases platform momentum, strategic priorities, and long-term value creation outlook Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug development industry and its regulators. The Investor Day presentation focused on how Simulations Plus is driving innovation and leading meaningful change across the drug development lifecycle—pairing its long-standing scientific reputation with modern cloud and AI

    1/21/26 4:05:00 PM ET
    $SLP
    EDP Services
    Technology

    $SLP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Simulations Plus Inc.

    SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

    8/8/24 2:18:03 PM ET
    $SLP
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

    SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

    2/13/24 5:13:58 PM ET
    $SLP
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

    SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

    2/12/24 4:59:04 PM ET
    $SLP
    EDP Services
    Technology

    $SLP
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus

    QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi

    6/12/24 8:58:00 AM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among

    12/1/20 4:05:00 PM ET
    $DIS
    $SLP
    $F
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    EDP Services
    Technology

    $SLP
    Financials

    Live finance-specific insights

    View All

    Simulations Plus Reports First Quarter Fiscal 2026 Financial Results

    Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. First Quarter 2026 Financial Highlights (as compared to first quarter 2025) Total revenue decreased 3% to $18.4 million Software revenue decreased 17% to $8.9 million, representing 48% of total revenue Services revenue increased 16% to $9.5 million, representing 52% of total revenue Gross profit was $10.9 million and gross mar

    1/8/26 4:05:00 PM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date

    Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 201-389-0879 (in

    12/17/25 7:50:00 AM ET
    $SLP
    EDP Services
    Technology

    Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results

    Reaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10  Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software revenue decreased 9% to $9.0 million, representi

    12/1/25 4:05:00 PM ET
    $SLP
    EDP Services
    Technology